<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58669">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856634</url>
  </required_header>
  <id_info>
    <org_study_id>242-12-232</org_study_id>
    <nct_id>NCT01856634</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis</brief_title>
  <official_title>Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the pediatric dose of delamanid  that is
      equivalent to the adult dose already shown to be effective against multidrug-resistant
      tuberculosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will investigate the pharmacokinetics (PK) and safety of delamanid administered
      twice daily for 10 days to pediatric patients aged 6 to 17 years who are also on therapy
      with an optimized background regimen.  The purpose of the trial is to determine which dose
      in pediatric MDR-TB patients will result in delamanid plasma exposure similar to efficacious
      plasma exposure in adult MDR-TB patients.  This is an age de-escalation trial in two groups:

      Group 1:  12 to 17 years (100 mg BID; n=6) Group 2:  6 to 11 years (50 mg BID; n =6)

      Dosing of patients in Group 2 will not start until all patients in Group 1 have completed
      the 18-day Treatment Period (10 days of dosing followed by 8 days of additional PK and
      safety assessments).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma Concentrations</measure>
    <time_frame>Days 1, 2, 10, 11, 13, 15, 18</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations (Cmax, tmax, AUC0-24h, accumulation ratio, apparent terminal elimination half-life, apparent total clearance)of delamanid and its metabolites  on Days 1, 2, 10, 11, 13, 15, 18.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>40 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of Reported Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Summary</measure>
    <time_frame>40 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Summary Statistics of subjects with clinically significant abnormal laboratory test results, vitals, EGGs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multidrug Resistant Tuberculosis</condition>
  <condition>Pediatric</condition>
  <arm_group>
    <arm_group_label>Group 1:  12 to 17 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: 100 mg Delamanid BID for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2:  6 - 11 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Delamanid BID for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg Delamanid</intervention_name>
    <description>100 mg BID for 10 days</description>
    <arm_group_label>Group 1:  12 to 17 years of age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg Delamanid</intervention_name>
    <description>50 mg BID for 10 days</description>
    <arm_group_label>Group 2:  6 - 11 years of age</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of MDR-TB OR

          -  Presumptive diagnosis of MDR TB including one of the following:

               -  Persistent cough lasting &gt; 2 weeks

               -  Fever, weight loss, and failure to thrive

               -  Chest radiograph consistent with TB

               -  Sputum smear positive for acid-fast bacilli AND

               -  Household contact of a person with known MDR TB or a person who died while
                  appropriately taking drugs for sensitive TB/OR

               -  On first-line TB treatment but with no clinical improvement

          -  Negative urine pregnancy test for female patients who have reached menarche

          -  Written informed consent/assent

        Exclusion Criteria:

          -  Positive test for HIV, previously identified as having HIV, or laboratory evidence of
             active hepatitis B or C

          -  History of allergy to metronidazole and any disease or condition in which
             metronidazole is required

          -  Use of amiodarone within 12 months or use of other predefined antiarrhythmic
             medications within 30 days prior to first dose of delamanid

          -  Serious concomitant conditions

          -  Preexisting cardiac conditions

          -  Abnormalities in Screening ECG (including AV block, BBB or hemi-block, QRS
             prolongation &gt; 120 msec, or QTcF &gt; 450 msec in both males and females)

          -  Concomitant condition such as renal impairment characterized by serum creatinine
             levels &gt;1.5 mg/dL, hepatic impairment (ALT or AST &gt; 3 x ULN), or hyperbilirubinemia
             characterized by total bilirubin &gt; 2x ULN

          -  Current diagnosis of severe malnutrition or kwashiorkor

          -  Rifampicin and/or moxifloxacin within 1 week prior to the first dose of delamanid

          -  Lansky Play Performance Score &lt; 50 or Karnofsky Score &lt; 50
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Hafkin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corey Best, MBA</last_name>
    <phone>919-544-8143</phone>
    <email>corey.best@otsuka-us.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>De La Salle Health Sciences Institute</name>
      <address>
        <city>Dasmari√±as City</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Melchor V G Frias</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria P S Austria-Cantimbuhan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hansel J Ybanez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita G Alvero</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brooklyn Chest Hospital</name>
      <address>
        <city>Ysterplaat</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anneke C Hesseling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Tuberculosis, Multidrug-Resistant</keyword>
  <keyword>Mycobacterium Infections</keyword>
  <keyword>Actinomycetales Infections</keyword>
  <keyword>Gram-Positive Infections</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Pediatric</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
